Seeking Alpha

LifeSci Advisors

 
(In beta) Send Us Feedback»
Title Symbol Long/
Short
Date of
publication
3m from
publication
6m from
publication
1y from
publication
BioCryst: The Next Orphan Drug $1B+ Company BCRX Long
8/2/2013
-4.9%
73.8%
113.6%
Acthar Gel Outperforms Methylprednisolone In Head-To-Head Study In MS Patients MNK Long
3/20/2013
34.8%
63.8%
91.8%
Questcor: Results Of Rheumatology Physician Survey Show Strong Uptake Of Acthar MNK Long
3/7/2013
19.5%
121.2%
120.8%
What Is Next For Transcept Pharmaceuticals After Disappointing Intermezzo Launch? PRTK Long
12/6/2012
2.6%
-42.8%
-32.7%
New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 ACHN Long
11/30/2012
4.0%
0.3%
-55.6%
Infinity Pharmaceuticals: Completion Of Phase I/II Trials May Drive Stock INFI Long
11/27/2012
60.5%
-3.5%
-42.2%
New Second Generation Combination Therapy For HCV - First Or Best In The Market (Part 1) GILD Long
11/16/2012
11.8%
47.7%
87.9%
Sarepta Part II: Commercial Potential Of Eteplirsen In The Next Hot Market For Orphan Drug SRPT Long
10/25/2012
20.9%
31.2%
85.3%
Avanir Pharmaceuticals: Pipeline Overview And Stock Valuation AVNR Long
10/24/2012
-0.7%
0.7%
62.1%
Aegerion's Lomitapide - FDA Approval, Strong Launch, Stock Price Increase Anticipated AEGR Long
10/24/2012
36.6%
88.4%
337.6%
Sarepta Part I: The Possibility Of An Accelerated Approval Of Eteplirsen SRPT Long
10/23/2012
1.8%
27.5%
74.4%
Questcor: Results Of Our Physician Survey Suggest Increased Sales For Acthar Gel MNK Long
10/8/2012
37.0%
50.5%
179.4%
Questcor: What's Really Changed? MNK Long
10/2/2012
34.9%
62.9%
210.2%
Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML ARIA Long
10/1/2012
-19.7%
-23.4%
-20.9%
Questcor Poised To Rally To $80 On Continued Sales Growth MNK Long
9/6/2012
-48.8%
-41.2%
32.3%
Ziopharm Oncology: Completion Of PICASSO 3 Clinical Trial Shows Promises For Driving Stock ZIOP Long
8/23/2012
-12.2%
-9.8%
-40.3%
Despite Legal And China Concerns, Prospects Are Strong For SciClone Pharmaceuticals SCLN Long
8/1/2012
6.7%
-1.9%
17.9%
Survey Of Surgeons Indicates Strong Launch For Exparel PCRX Long
7/5/2012
14.5%
10.6%
90.0%
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis AEGR Long
7/2/2012
0.4%
83.2%
368.7%
Aegerion Pharmaceuticals: We Are Bullish On The Lomitapide Story AEGR Long
6/8/2012
-4.5%
27.0%
366.0%
YM Biosciences: The Next Way To Get Long Myelofibrosis GILD Long
5/3/2012
3.4%
-11.8%
-
Threshold Pharmaceuticals: TH-302 Phase IIb Clinical Results In First-Line Pancreatic Cancer THLD Long
4/27/2012
-1.0%
-39.4%
-31.6%
Second Physician Survey Supports Prescription Data: Expecting 1Q Fusilev Growth SPPI Long
4/17/2012
64.6%
21.9%
-28.7%
Spectrum Pharmaceutical: FUSILEV Sales Accelerating In 1Q, Stock Should Move To New Levels SPPI Long
3/21/2012
1.8%
-5.6%
-46.0%
Seattle Genetics' Adcetris Launch: Second Survey Reveals Additional Insights SGEN Long
2/10/2012
2.6%
28.6%
63.4%
Jakafi Launch: Survey Reveals Upside To Stock INCY Long
1/24/2012
2.6%
30.7%
-0.2%
Survey: Spectrum's Fusilev Medication Sales Poised For More Growth SPPI Long
10/25/2011
68.6%
25.4%
24.7%
Optimer Pharma's Diarrhea Drug Launch Looking Strong Based On Survey OPTR Long
10/18/2011
-8.0%
-4.1%
-20.9%